KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature

被引:29
作者
de Reynies, Aurelien [1 ]
Biol, Valerie [2 ]
Milano, Gerard [3 ]
Faivre, Jean [4 ]
Laurent-Puig, Pierre [5 ]
机构
[1] Ligue Natl Contre Canc, Paris, France
[2] Inst Gustave Roussy, Villejuif, France
[3] Inst Antoine Lacassagne, Nice, France
[4] Univ Bourgogne, Ctr Hosp Univ Dijon, F-21004 Dijon, France
[5] Univ Paris 05, AP HP, Inst Natl St Rech Med U775, Paris, France
关键词
D O I
10.1200/JCO.2007.15.9186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:228 / 2230
页数:4
相关论文
共 4 条
  • [1] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    De Roock, W.
    Piessevaux, H.
    De Schutter, J.
    Janssens, M.
    De Hertogh, G.
    Personeni, N.
    Biesmans, B.
    Van Laethem, J. -L.
    Peeters, M.
    Humblet, Y.
    Van Cutsem, E.
    Tejpar, S.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 508 - 515
  • [2] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
    Di Fiore, F.
    Blanchard, F.
    Charbonnier, F.
    Le Pessot, F.
    Lamy, A.
    Galais, M. P.
    Bastit, L.
    Killian, A.
    Sesboue, R.
    Tuech, J. J.
    Queuniet, A. M.
    Paillot, B.
    Sabourin, J. C.
    Michot, F.
    Michel, P.
    Frebourg, T.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1166 - 1169
  • [3] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Khambata-Ford, Shirin
    Garrett, Christopher R.
    Meropol, Neal J.
    Basik, Mark
    Harbison, Christopher T.
    Wu, Shujian
    Wong, Tai W.
    Huang, Xin
    Takimoto, Chris H.
    Godwin, Andrew K.
    Tan, Benjamin R.
    Krishnamurthi, Smitha S.
    Burris, Howard A., III
    Poplin, Elizabeth A.
    Hidalgo, Manuel
    Baselga, Jose
    Clark, Edwin A.
    Mauro, David J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3230 - 3237
  • [4] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lièvre, A
    Bachet, JB
    Le Corre, D
    Boige, V
    Landi, B
    Emile, JF
    Côté, JF
    Tomasic, G
    Penna, C
    Ducreux, M
    Rougier, P
    Penault-Llorca, F
    Laurent-Puig, P
    [J]. CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995